Developmental and epileptic encephalopathies (DEEs) have evolved from symptom control toward precision neurology, with the market anchored by EPIDIOLEX (cannabidiol, Jazz Pharmaceuticals), initially approved in the US in 2018 for Dravet syndrome and Lennox–Gastaut syndrome (LGS) and later expanded to tuberous sclerosis complex (TSC) in 2020, and FINTEPLA (fenfluramine, UCB), approved for Dravet syndrome in 2020 and LGS in 2022. The market has further expanded with ZTALMY (ganaxolone, Marinus Pharmaceuticals), approved in 2022 as the first therapy specifically indicated for CDKL5 deficiency disorder, reinforcing the shift toward mechanism-based and syndrome-specific tr...
